A look at how the legislation has evolved over the past year and a half. (Also see "The Evolution Of 21^st Century Cures Legislation" - Pink Sheet, 30 November, 2016.)
FDA’s getting $500m in additional revenue as part of the bill – probably. (Also see "US FDA Getting More Money Up Front Under Cures Bill Revisions" - Pink Sheet, 1 December, 2016.)
The agency may only meet the minimum requirements for establishing intercenter institutes. (Also see "Cures Bill Authorizes 'Intercenter Institutes,' But Will US FDA Create Them?" - Pink Sheet, 28 November, 2016.)
Congress expects FDA to take patient input seriously. (Also see "21^st Century Cures Revisions Tell FDA To Highlight ‘Patient Experience Data’" - Pink Sheet, 28 November, 2016.)

Rx For Industry: Key Provisions Of The 21st Century Cures Act

More from Anti-infective